eFFECTOR Therapeutics (EFTR) Competitors $0.0002 0.00 (-66.67%) As of 03/27/2025 03:31 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock EFTR vs. NAVB, EVLO, CMRA, GNCAQ, GNCA, ARDS, STAB, CALA, AMPE, and PXMDShould you be buying eFFECTOR Therapeutics stock or one of its competitors? The main competitors of eFFECTOR Therapeutics include Navidea Biopharmaceuticals (NAVB), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), Calithera Biosciences (CALA), Ampio Pharmaceuticals (AMPE), and PaxMedica (PXMD). These companies are all part of the "pharmaceutical products" industry. eFFECTOR Therapeutics vs. Navidea Biopharmaceuticals Evelo Biosciences Comera Life Sciences Genocea Biosciences Genocea Biosciences Aridis Pharmaceuticals Statera Biopharma Calithera Biosciences Ampio Pharmaceuticals PaxMedica Navidea Biopharmaceuticals (NYSE:NAVB) and eFFECTOR Therapeutics (NASDAQ:EFTR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, community ranking, media sentiment, profitability, analyst recommendations, risk and valuation. Does the MarketBeat Community favor NAVB or EFTR? eFFECTOR Therapeutics received 23 more outperform votes than Navidea Biopharmaceuticals when rated by MarketBeat users. Likewise, 79.31% of users gave eFFECTOR Therapeutics an outperform vote while only 0.00% of users gave Navidea Biopharmaceuticals an outperform vote. CompanyUnderperformOutperformNavidea BiopharmaceuticalsOutperform VotesNo VotesUnderperform Votes80100.00% eFFECTOR TherapeuticsOutperform Votes2379.31% Underperform Votes620.69% Is NAVB or EFTR more profitable? Company Net Margins Return on Equity Return on Assets Navidea BiopharmaceuticalsN/A N/A N/A eFFECTOR Therapeutics N/A N/A N/A Does the media prefer NAVB or EFTR? In the previous week, Navidea Biopharmaceuticals had 1 more articles in the media than eFFECTOR Therapeutics. MarketBeat recorded 1 mentions for Navidea Biopharmaceuticals and 0 mentions for eFFECTOR Therapeutics. Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled eFFECTOR Therapeutics'average media sentiment score. Company Overall Sentiment Navidea Biopharmaceuticals Neutral eFFECTOR Therapeutics Neutral Which has more volatility & risk, NAVB or EFTR? Navidea Biopharmaceuticals has a beta of 1.87, indicating that its share price is 87% more volatile than the S&P 500. Comparatively, eFFECTOR Therapeutics has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500. Which has higher valuation and earnings, NAVB or EFTR? Navidea Biopharmaceuticals has higher earnings, but lower revenue than eFFECTOR Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNavidea Biopharmaceuticals$8.13K4.93-$15.18MN/AN/AeFFECTOR Therapeutics$3.55M0.00-$35.81M-$13.080.00 Do institutionals and insiders hold more shares of NAVB or EFTR? 0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. Comparatively, 57.7% of eFFECTOR Therapeutics shares are held by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are held by insiders. Comparatively, 4.7% of eFFECTOR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryNavidea Biopharmaceuticals beats eFFECTOR Therapeutics on 5 of the 9 factors compared between the two stocks. Remove Ads Get eFFECTOR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for EFTR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EFTR vs. The Competition Export to ExcelMetriceFFECTOR TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1,000.00$6.93B$5.64B$7.83BDividend YieldN/A2.73%4.57%4.00%P/E Ratio0.007.1723.1418.67Price / Sales0.00221.06388.4891.04Price / CashN/A65.6738.1634.64Price / Book0.006.396.894.23Net Income-$35.81M$142.12M$3.20B$247.15M7 Day PerformanceN/A-5.12%-2.98%-2.19%1 Month PerformanceN/A-7.44%1.67%-5.68%1 Year PerformanceN/A-8.65%9.87%-0.67% eFFECTOR Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EFTReFFECTOR TherapeuticsN/A$0.00-66.7%N/A-100.0%$1,000.00$3.55M0.0010Upcoming EarningsNAVBNavidea BiopharmaceuticalsN/A$0.00-50.0%N/A-98.9%$10,000.00$8,126.000.0010Gap DownEVLOEvelo BiosciencesN/A$0.00flatN/A-98.9%$9,000.00N/A0.00120Upcoming EarningsCMRAComera Life SciencesN/A$0.00flatN/A-99.4%$6,000.00$1.00M0.002GNCAQGenocea BiosciencesN/AN/AN/AN/A$6,000.00N/A0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6,000.00$1.91M0.0070Analyst ForecastNews CoverageARDSAridis PharmaceuticalsN/A$0.00flatN/A-99.9%$5,000.00$3.09M0.0030STABStatera BiopharmaN/A$0.00flatN/A-83.3%$5,000.00N/A0.0020CALACalithera BiosciencesN/A$0.00flatN/AN/A$3,000.00N/A0.0060AMPEAmpio PharmaceuticalsN/A$0.00flatN/A-99.9%$2,000.00N/A0.0020PXMDPaxMedicaN/A$0.00flatN/AN/A$2,000.00N/A0.002 Remove Ads Related Companies and Tools Related Companies Navidea Biopharmaceuticals Alternatives Evelo Biosciences Alternatives Comera Life Sciences Alternatives Genocea Biosciences Alternatives Genocea Biosciences Alternatives Aridis Pharmaceuticals Alternatives Statera Biopharma Alternatives Calithera Biosciences Alternatives Ampio Pharmaceuticals Alternatives PaxMedica Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EFTR) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredTrump’s Treasure Map [Pic inside]We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men...Paradigm Press | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding eFFECTOR Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share eFFECTOR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
